Zobrazeno 1 - 7
of 7
pro vyhledávání: '"329"'
Autor:
Romain Guieze, Anne Calleja, Loic Ysebaert, Anne-Sophie Michallet, Emmanuelle Ferrant, Aline Clavert, Fontanet Bijou, Anne Quinquenel, Annie Brion, Kamel Laribi
Publikováno v:
61st Annual Meeting and Exposition of the American Society of Hematology
61st Annual Meeting and Exposition of the American Society of Hematology, Dec 2019, Orlando, United States. 134 (Suppl 1), pp.1741, 2019, Blood
61st Annual Meeting and Exposition of the American Society of Hematology, Dec 2019, Orlando, United States. 134 (Suppl 1), pp.1741, 2019, Blood
Ibrutinib has revolutionized the management of RR CLL in the past 5 years, improving overall survival (OS) over standard chemo-immunotherapies (CIT) in the registration trials HELIOS and RESONATE. Recently, based on these two studies, a score has bee
Autor:
Dirk Huebner, Craig H. Moskowitz, Patrick J. Stiff, Jerzy Holowiecki, Andy I. Chen, Dzhelil Osmanov, Auayporn Nadamanee, Veronika Bachanova, Tamas Masszi, Emily K. Larsen, Muneer H. Abidi, John W. Sweetenham, Naomi N. H. Hunder, Anna Sureda, Jan Walewski, Alessandro M. Gianni, Angelo Michele Carella, Edward Agura
Publikováno v:
Blood. 124:673-673
Background For the past 20 years, high-dose therapy plus autologous stem cell transplant (ASCT) has been the standard of care for patients (pts) with chemosensitive relapsed/refractory Hodgkin lymphoma (HL), providing a cure for approximately 50% of
Autor:
Yuan-Shung Huang, Brian T. Fisher, Richard Aplenc, Karen R. Rabin, Kelly D. Getz, Jennifer J. Wilkes, Viviane C. Cahen, Yimei Li, Lena E. Winestone, Amanda M. DiNofia, M. Monica Gramatges, Alix E. Seif, Caitlin W Elgarten
Publikováno v:
Blood. 132:624-624
Administrative databases can be used to study outcomes including patients outside of clinical trials and have been used to identify relapse and HSCT in adult and adolescent/young adult leukemia populations. However, there are no published studies usi
Autor:
Markus Loeffler, Norbert Schmitz, Randy D. Gascoyne, Roopesh Kansara, Michael Pfreundschuh, Bertram Glass, Samira Zeynalova, Kerry J. Savage, David Scott, Diego Villa, Laurie H. Sehn, Joseph M. Connors, Maike Nickelsen, Marita Ziepert
Publikováno v:
Blood. 124:394-394
[Graphic][1] Introduction : Despite the improvement of outcome of aggressive B-cell lymphomas in the rituximab treatment era, central nervous system (CNS) relapse continues to pose a significant management problem. It remains a challenge to select pa
Autor:
Kara Cetin, Michelle Gleeson, Robert I. Griffiths, Aaron J. Katz, Michael A. Kelsh, Mark D. Danese
Publikováno v:
Blood. 122:3877-3877
Background ALL is the most common childhood cancer, with remission rates exceeding 90% and 5-year survival exceeding 80% in pediatric patients. However, in older adult patients, ALL is associated with high morbidity and mortality. Nonetheless, becaus
Autor:
Heinz Haverkamp, Peter Borchmann, Jana Markova, Zdenek Kral, Andreas Engert, Carsten Kobe, Hans Theodor Eich, Josée M. Zijlstra, Anthony D. Ho, Harald Stein, Rolf-Peter Müller, Christoph Renner, Markus Dietlein, Volker Diehl
Publikováno v:
Blood. 118:589-589
Abstract 589FN2 Purpose: Intensified chemotherapy with eight cycles of BEACOPPescalated in advanced stage Hodgkin lymphoma (HL) is highly effective but also associated with relevant treatment related toxicity. In addition, the need for radiotherapy i
Autor:
John A. Liu Yin, Lars Kjeldsen, Robert Kerrin Hills, Brenda Gibson, Alan Kenneth Burnett, Donald Milligan, Ann Hunter, Archie G. Prentice, Anthony H. Goldstone, Keith Wheatley, Nigel H. Russell
Publikováno v:
Blood. 114:484-484
Abstract 484 On behalf of the NCRI AML Working Group, United Kingdom There is a general acceptance that survival in younger patients (75% relapse remains a problem. Optimisation of induction and defining the schedule and duration of post-induction ch